JPMorgan Chase & Co. lifted its position in shares of Enochian Biosciences, Inc. (NASDAQ:ENOB) by 265.4% in the 4th quarter, Holdings Channel reports. The fund owned 40,630 shares of the company’s stock after buying an additional 29,511 shares during the period. JPMorgan Chase & Co.’s holdings in Enochian Biosciences were worth $120,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in ENOB. BlackRock Inc. grew its position in shares of Enochian Biosciences by 9.8% during the fourth quarter. BlackRock Inc. now owns 824,530 shares of the company’s stock worth $2,432,000 after acquiring an additional 73,766 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Enochian Biosciences in the fourth quarter worth about $163,000. Marshall Wace LLP acquired a new stake in Enochian Biosciences in the first quarter worth about $60,000. Barclays PLC lifted its holdings in Enochian Biosciences by 112.1% in the fourth quarter. Barclays PLC now owns 13,401 shares of the company’s stock worth $39,000 after purchasing an additional 7,082 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Enochian Biosciences by 24.2% in the fourth quarter. Rhumbline Advisers now owns 14,932 shares of the company’s stock worth $44,000 after purchasing an additional 2,905 shares during the period. Institutional investors and hedge funds own 5.11% of the company’s stock.
ENOB stock opened at $3.72 on Wednesday. The company has a 50-day simple moving average of $3.44 and a 200 day simple moving average of $3.37. Enochian Biosciences, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $13.43. The company has a quick ratio of 7.29, a current ratio of 7.29 and a debt-to-equity ratio of 0.04.
About Enochian Biosciences
Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine.
Recommended Story: Stop Order
Want to see what other hedge funds are holding ENOB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enochian Biosciences, Inc. (NASDAQ:ENOB).
Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.